SITC

Shattuck Labs Reports Third Quarter 2020 Financial Results and Recent Business Highlights

Retrieved on: 
Friday, November 13, 2020
Medical specialties, Medicine, Clinical medicine, Oncology, Society for Immunotherapy of Cancer, SITC, Cancer, Ovarian cancer

The Phase 1 trial will initially evaluate the safety, tolerability, and anti-tumor effects of SL-172154 in patients with ovarian cancer.

Key Points: 
  • The Phase 1 trial will initially evaluate the safety, tolerability, and anti-tumor effects of SL-172154 in patients with ovarian cancer.
  • In November 2020, Shattuck presented an update on the progress of the GADLEN platform at the Society for Immunotherapy of Cancer (SITC) Meeting.
  • Research and Development (R&D) Expenses: R&D expenses were $11.8 million for the third quarter of 2020, as compared to $7.9 million for the third quarter of 2019.
  • General and Administrative (G&A) Expenses: G&A expenses were $2.5 million for the third quarter of 2020, as compared to $1.4 million for the third quarter of 2019.

Atreca Reports Third Quarter 2020 Financial Results and Recent Corporate Developments

Retrieved on: 
Thursday, November 12, 2020
Clinical medicine, Medicine, Medical specialties, Immune system, Clusters of differentiation, Checkpoint inhibitor, Cancer immunotherapy, PD-L1, Programmed cell death protein 1, Immunotherapy, SITC

SOUTH SAN FRANCISCO, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced financial results for the third quarter ended September 30, 2020, and provided an overview of recent developments.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced financial results for the third quarter ended September 30, 2020, and provided an overview of recent developments.
  • We recently presented preclinical data at SITC 2020 further highlighting the potential for ATRC-101 as a combination therapy with checkpoint inhibitors targeting the PD-1/PD-L1 axis.
  • We expect to initiate combination studies with a checkpoint inhibitor as well as with chemotherapy, and to commence monotherapy expansion cohorts, in 2021.
  • Atreca presented two posters describing preclinical evaluations of ATRC-101 at the 35th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2020).

Atara Biotherapeutics Presents New Preclinical Data on ATA3271, a Next-Generation Allogeneic Mesothelin-Targeted CAR T to Treat Solid Tumors, at the 35th Society for Immunotherapy of Cancer Annual Meeting (SITC 2020)

Retrieved on: 
Thursday, November 12, 2020
Oncology, Health, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Medicine, Clinical medicine, Medical specialties, Society for Immunotherapy of Cancer, SITC, Cancer immunotherapy, Immunotherapy

These data are being featured in a poster presentation at the 35th Society for Immunotherapy of Cancer Annual Meeting (SITC 2020), November 11-14, 2020.

Key Points: 
  • These data are being featured in a poster presentation at the 35th Society for Immunotherapy of Cancer Annual Meeting (SITC 2020), November 11-14, 2020.
  • Such innovative CAR T design addresses key hurdles for realizing the potential for CAR T therapies in solid tumor settings, said Jakob Dupont, Global Head of Research and Development at Atara.
  • Results presented at SITC detail findings from in vitro and in vivo evaluation of ATA3271.
  • We also believe that our allogeneic EBV CAR T-cell platform may prevent cellular exhaustion and augment in vivo expansion.

SITC Announces Creation of Steven A. Rosenberg, MD, PhD, Endowed Scholars Fund Supporting Cancer Immunotherapy Research; Names Eric Tran, PhD, Inaugural Recipient

Retrieved on: 
Wednesday, November 11, 2020
Medicine, Medical specialties, Clinical medicine, Society for Immunotherapy of Cancer, SITC, Immunotherapy, Cancer immunotherapy, Steven Rosenberg

MILWAUKEE, Nov. 11, 2020 /PRNewswire-PRWeb/ -- The Society for Immunotherapy of Cancer (SITC) is pleased to announce the creation of the Steven A. Rosenberg, MD, PhD, Endowed Scholars Fund.

Key Points: 
  • MILWAUKEE, Nov. 11, 2020 /PRNewswire-PRWeb/ -- The Society for Immunotherapy of Cancer (SITC) is pleased to announce the creation of the Steven A. Rosenberg, MD, PhD, Endowed Scholars Fund.
  • As Chief of Surgery, he oversees an extensive clinical program to translate scientific advances into effective immunotherapies for patients with cancer.
  • In 2012, SITC established the Forward Fund in to stimulate the future of science through the development and application of cancer immunotherapy.
  • Learn more about SITC, our educational offerings and other resources at sitcancer.org and follow us on Twitter , LinkedIn , Facebook and YouTube .

Xilio Therapeutics to Present Data on Tumor-Selective Immunotherapies at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Retrieved on: 
Tuesday, November 10, 2020
Biotechnology, Health, Science, Research, Oncology, Medicine, Clinical medicine, Medical specialties, Cancer immunotherapy, Society for Immunotherapy of Cancer, Cancer, SITC, Immunotherapy, Biotechnology

The data will be shared at the 35th Annual Meeting of The Society for Immunotherapy of Cancer ( SITC 2020 ) taking place virtually November 9 14, 2020.

Key Points: 
  • The data will be shared at the 35th Annual Meeting of The Society for Immunotherapy of Cancer ( SITC 2020 ) taking place virtually November 9 14, 2020.
  • The abstract featuring data on XTX201, Xilios tumor-selective IL-2, will be shared in a virtual poster viewing session.
  • The abstract featuring data on the tumor-selective aCTLA4 antibody XTX101 will be shared in an oral presentation and in a virtual poster viewing session.
  • Xilio Therapeutics is a biotechnology company that uses its proprietary technology to develop next-generation cancer immunotherapies.

Surface Oncology Reports Financial Results and Corporate Highlights for Third Quarter 2020

Retrieved on: 
Tuesday, November 10, 2020
Medicine, Clinical medicine, Medical specialties, Cancer immunotherapy, Oncology, Immunotherapy, Society for Immunotherapy of Cancer, SITC

CAMBRIDGE, Mass., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today reported financial results and corporate highlights for the third quarter 2020, as well as anticipated corporate milestones for the remainder of the year.

Key Points: 
  • CAMBRIDGE, Mass., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today reported financial results and corporate highlights for the third quarter 2020, as well as anticipated corporate milestones for the remainder of the year.
  • The third quarter of 2020 was one of strong execution for Surface on several fronts, said Jeff Goater, chief executive officer.
  • Selected Anticipated Near-term Corporate Milestones:
    Preclinical data presentations anticipated at Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting, November 1114 2020.
  • Surface Oncology continues to project that current cash and cash equivalents are sufficient to fund the Company into 2022.

Oncocyte to Present DetermaIO™ Test Data at the 2020 Society for Immunotherapy of Cancer (SITC) Conference

Retrieved on: 
Monday, November 9, 2020
Clinical medicine, Medicine, Medical specialties, Virotherapy, Society for Immunotherapy of Cancer, Checkpoint inhibitor, Cancer immunotherapy, SITC, Oncology, Immunotherapy, Cancer, ICI

IRVINE, Calif., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across the cancer care continuum, today announced plans to present data at the Society for Immunotherapy of Cancer (SITC) 2020 Virtual Conference on its test, DetermaIO.

Key Points: 
  • IRVINE, Calif., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across the cancer care continuum, today announced plans to present data at the Society for Immunotherapy of Cancer (SITC) 2020 Virtual Conference on its test, DetermaIO.
  • These data indicate that DetermaIO can identify viable treatment pathways for many cancer patients who are resistant to immune checkpoint inhibitors (ICIs).
  • That results in the significant need for a test like DetermaIO to predict whether patients are likely to respond to ICI therapy.
  • In fact, likelihood of response is the principal clinical question driving the emerging $3B+ U.S. ICI therapy selection testing market.

Corvus Completes Enrollment in Phase 1 Study of CPI-006 for Patients with COVID-19 and Presents Study Data at 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Retrieved on: 
Monday, November 9, 2020
Medical specialties, Medicine, Immunology, Society for Immunotherapy of Cancer, SITC, Cancer immunotherapy

Updated data from the study is being presented this week in a poster presentation and an oral presentation at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting.

Key Points: 
  • Updated data from the study is being presented this week in a poster presentation and an oral presentation at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting.
  • The data presented at SITC include results from 22 patients enrolled in the Phase 1 study utilizing a cut-off date of November 4, 2020.
  • All evaluable patients had prompt anti-SARS-CoV-2 antibody responses within 7 days of administration of CPI-006 at all dose levels.
  • Corvus announced that it has completed enrollment in the final cohort of the Phase 1/1b cancer clinical trial.

Celldex Presents Data from Oncology Portfolio at SITC 2020

Retrieved on: 
Monday, November 9, 2020
Medicine, Clinical medicine, Medical specialties, Society for Immunotherapy of Cancer, SITC, Cancer immunotherapy, Immunotherapy, CD40, CDX

-- Agonist anti-CD40 mAb CDX-1140 demonstrates best-in-class potential; additional expansion cohorts initiated--

Key Points: 
  • -- Agonist anti-CD40 mAb CDX-1140 demonstrates best-in-class potential; additional expansion cohorts initiated--
    HAMPTON, N.J., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced data from multiple presentations at the Society for Immunotherapy of Cancers (SITC) 35th Anniversary Annual Meeting & Pre-Conference Programs (SITC 2020).
  • We also recently initiated an expansion cohort with chemotherapy in pancreatic cancer which is supported by strong preclinical studies and promising early clinical data with CD40 agonist antibodies.
  • The update presented at SITC 2020 focused on patients treated at the MTD from both the monotherapy (n=25) and CDX-301 (n=16) combination cohorts.
  • At SITC 2020 , analysis was focused on patients treated at the MTD and recommended dose of 1.5 mg/kg.

4D Pharma Presents New Data from Two MRx0518 Clinical Trials at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

Retrieved on: 
Monday, November 9, 2020
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical trials, Other Health, Health care, Health, Medical specialties, SITC, Society for Immunotherapy of Cancer, Clinical trial, Cancer immunotherapy, MRx0518, 4D pharma

The data is presented in three posters at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2020, November 9-14, 2020.

Key Points: 
  • The data is presented in three posters at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2020, November 9-14, 2020.
  • 4D pharma will also host a virtual key opinion leader (KOL) event to review these data on Wednesday, November 11, 2020 at 1:00pm GMT (8:00am ET).
  • The data generated from these trials provide us with huge confidence not only with moving forward with MRx0518 as a novel immunotherapy for the treatment of cancer, but also our MicroRx platform.
  • 4D pharma will host a virtual event for investors and analysts to review the data presented from two ongoing clinical trials of MRx0518 at SITC 2020.